文献速递心脑血管急症

真实世界人群中替奈普酶与阿替普酶治疗急性缺血性卒中的安全性和有效性

Safety and efficacy of tenecteplase versus alteplase for acute ischemic stroke in a real-world patient population.
PubMed 文献 · Am J Emerg Med · 2026-09-02
一句话结论真实世界回顾性研究显示,急性缺血性卒中4.5小时内使用替奈普酶与阿替普酶在症状性颅内出血及有效性结局上无统计学显著差异。

该回顾性观察性研究纳入2020年5月至2024年6月期间症状发作4.5小时内接受替奈普酶或阿替普酶治疗的成人急性缺血性卒中患者478例(替奈普酶255例,阿替普酶223例),中位年龄72岁,33%为轻型卒中(NIHSS<5)。主要终点症状性颅内出血发生率替奈普酶组3.9% vs 阿替普酶组3.1%(p=0.65),大出血20.4% vs 15.7%(p=0.18),均无统计学显著差异;次要结局无差异。分层分析中年龄<80岁和入院NIHSS≥5与出血事件相关,但逻辑回归模型中未保持。结论认为两种溶栓药物安全性和有效性无显著差异,但II类错误可能限制发现。

要点

  • 主要终点症状性颅内出血:替奈普酶3.9% vs 阿替普酶3.1%(p=0.65),无统计学显著差异。
  • 大出血事件:替奈普酶20.4% vs 阿替普酶15.7%(p=0.18),数值上替奈普酶组更高但未达统计学显著。
  • 次要结局(NIHSS变化、血管性水肿、改良Rankin量表变化、住院时长、死亡率)两组间无差异。
  • 分层分析中年龄<80岁和入院NIHSS≥5与出血事件相关,但逻辑回归模型中未保持。
  • 研究纳入33%轻型卒中(NIHSS<5)患者,中位年龄72岁,提供老年和相对轻型卒中人群的真实世界数据。

适用人群与场景

  • 成人急性缺血性卒中患者,症状发作4.5小时内接受替奈普酶或阿替普酶治疗(2020年5月至2024年6月)。
  • 中位年龄72岁(IQR 61-83),33%为轻型卒中(NIHSS<5)。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:回顾性观察性研究;样本量478例(替奈普酶255例[53.2%],阿替普酶223例[46.7%]);单中心/多中心原文未提及。
  • 主要终点症状性颅内出血:替奈普酶3.9% vs 阿替普酶3.1%,p=0.65,无统计学显著差异。
  • 大出血:替奈普酶20.4% vs 阿替普酶15.7%,p=0.18,无统计学显著差异。
  • 次要结局(NIHSS变化、血管性水肿、改良Rankin量表变化、住院时长、死亡率)无差异。
  • 分层分析:年龄<80岁和入院NIHSS≥5与出血事件相关,但逻辑回归模型中未保持。

证据类型、等级与局限

  • 证据类型:回顾性观察性研究。
  • 局限:II类错误可能限制 findings;原文未提及证据等级或推荐强度。

对床旁实践的改变

  • 在真实世界老年(中位72岁)及相对轻型卒中(33% NIHSS<5)人群中,替奈普酶与阿替普酶的安全性和有效性无统计学显著差异,可作为溶栓药物选择的参考。
  • 替奈普酶组大出血数值上更高(20.4% vs 15.7%),虽未达统计学显著,临床决策时需结合患者个体出血风险权衡。
  • 年龄<80岁和入院NIHSS≥5与出血事件相关但逻辑回归未保持,不能作为决策阈值。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

PURPOSE: We compared safety and efficacy of tenecteplase (TNK) and alteplase for acute ischemic stroke (AIS) in a real-world setting.

METHODS: Retrospective, observational, study of adult AIS patients who received TNK or alteplase within 4.5 h of symptom onset from May 2020-June 2024. Primary outcome was symptomatic intracranial hemorrhage (sICH) occurrence. Secondary outcomes were major and minor bleeding occurrence, National Institutes of Health Stroke Scale (NIHSS) score changes, angioedema occurrence, modified Rankin Scale changes, length of stay, and mortality. Univariate and stratified analyses were conducted to assess bleeding differences and specifically in subpopulations often underrepresented in the literature (advanced age, minor strokes [NIHSS, < 5], and poor pre-stroke functional status).

RESULTS: 478 patients were included; 255 (53.2%) TNK and 223 (46.7%) alteplase (median age 72 years [IQR 61-83], 33% minor strokes [33%]). There were numerically more sICH and other major bleeding events in the TNK group; 3.9%, vs. 3.1%, p = 0.65 and 20.4% vs. 15.7%, p = 0.18, respectively, although not statistically significant. There were no differences in secondary outcomes. Age < 80 years and NIHSS ≥5 at presentation were associated with a bleeding event on stratified analysis, however not maintained in the logistic regression model.

CONCLUSIONS: There were no statistically significant differences in safety or efficacy between TNK and alteplase for AIS. These results provide real-world experience especially in a large, older patient population, with relatively minor stroke. Type II error may limit findings. Research is needed to identify patient, stroke, or fibrinolytic agent related factors that may increase bleeding occurrence.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Toole S, Bishop R, Acquisto NM, et al. Safety and efficacy of tenecteplase versus alteplase for acute ischemic stroke in a real-world patient population. Am J Emerg Med. 2026. PMID: 42715780. doi:10.1016/j.ajem.2026.08.048

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。